WallStSmart

Boston Scientific Corp (BSX)vsNeuroone Medical Technologies Corp (NMTC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Boston Scientific Corp generates 168290% more annual revenue ($21.00B vs $12.47M). BSX leads profitability with a 17.5% profit margin vs -59.7%. BSX earns a higher WallStSmart Score of 72/100 (B).

BSX

Strong Buy

72

out of 100

Grade: B

Growth: 7.3Profit: 7.0Value: 6.7Quality: 5.5
Piotroski: 5/9Altman Z: 1.78

NMTC

Avoid

28

out of 100

Grade: F

Growth: 7.3Profit: 2.0Value: 5.0Quality: 6.5
Piotroski: 5/9Altman Z: -8.06
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BSXOvervalued (-10.0%)

Margin of Safety

-10.0%

Fair Value

$39.07

Current Price

$42.98

$3.91 premium

UndervaluedFair: $39.07Overvalued

Intrinsic value data unavailable for NMTC.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BSX6 strengths · Avg: 8.2/10
Market CapQuality
$62.29B9/10

Large-cap with strong market position

PEG RatioValuation
0.608/10

Growing faster than its price suggests

P/E RatioValuation
17.5x8/10

Attractively priced relative to earnings

Price/BookValuation
2.5x8/10

Reasonable price relative to book value

Operating MarginProfitability
22.9%8/10

Strong operational efficiency at 22.9%

Free Cash FlowQuality
$1.28B8/10

Generating 1.3B in free cash flow

NMTC2 strengths · Avg: 9.0/10
Debt/EquityHealth
0.0210/10

Conservative balance sheet, low leverage

Revenue GrowthGrowth
16.3%8/10

16.3% revenue growth

Areas to Watch

BSX1 concerns · Avg: 4.0/10
Altman Z-ScoreHealth
1.784/10

Distress zone — elevated risk

NMTC4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$14.75M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-123.6%2/10

ROE of -123.6% — below average capital efficiency

Free Cash FlowQuality
$-1.10M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : BSX

The strongest argument for BSX centers on Market Cap, PEG Ratio, P/E Ratio. Profitability is solid with margins at 17.5% and operating margin at 22.9%. PEG of 0.60 suggests the stock is reasonably priced for its growth.

Bull Case : NMTC

The strongest argument for NMTC centers on Debt/Equity, Revenue Growth. Revenue growth of 16.3% demonstrates continued momentum.

Bear Case : BSX

The primary concerns for BSX are Altman Z-Score.

Bear Case : NMTC

The primary concerns for NMTC are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

BSX profiles as a mature stock while NMTC is a growth play — different risk/reward profiles.

NMTC carries more volatility with a beta of 0.64 — expect wider price swings.

NMTC is growing revenue faster at 16.3% — sustainability is the question.

BSX generates stronger free cash flow (1.3B), providing more financial flexibility.

Bottom Line

BSX scores higher overall (72/100 vs 28/100), backed by strong 17.5% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Neuroone Medical Technologies Corp

HEALTHCARE · MEDICAL DEVICES · USA

NeuroOne Medical Technologies Corporation is a medical technology company. The company is headquartered in Eden Prairie, Minnesota.

Visit Website →

Want to dig deeper into these stocks?